| The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac (NCT03651544) | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 2018-10-15 |
| Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A (NCT02572817) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-11-01 |
| Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents (NCT02250274) | Marshfield Clinic Research Foundation | 2014-09-01 |
| Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China (NCT01459081) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2011-10-01 |
| Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment (NCT01146535) | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | 2011-01-01 |
| Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza (NCT01175122) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-09-01 |
| Blood and Plasma Collection For Use in Future Clinical Trials (NCT01136057) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-04-01 |
| A Pilot Study for Collection of Anti-Influenza A Immune Plasma (NCT00984451) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-09-01 |
| Antiviral Therapy for Influenza A H1N1 (NCT00985582) | South East Asia Infectious Disease Clinical Research Network | 2009-09-01 |
| Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit (NCT00844155) | University of Manitoba | 2009-03-01 |
| Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children (NCT00491985) | Sanofi Pasteur, a Sanofi Company | 2007-06-01 |